Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Double blind, randomized, parallel groups study of Pitolisant versus placebo, in narcoleptic
patients experiencing EDS, and cataplexy (minimum of 3 complete or partial cataplexy attacks
per week).
The patients will be treated during 7 weeks with Pitolisant or placebo.